Abstract
Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| Volume | 34 |
| Issue number | SUPPL. 1 |
| DOIs | |
| Publication status | Published - 2013 |
Fingerprint
Keywords
- Almotriptan
- Arterial hypertension
- Frovatriptan
- Migraine
- Rizatriptan
- Zolmitriptan
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health
- Dermatology
- Medicine(all)
Cite this
Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects : A review of randomized studies. / Tullo, V.; Bussone, G.; Omboni, S.; Barbanti, P.; Cortelli, P.; Curone, M.; Peccarisi, C.; Benedetto, C.; Pezzola, D.; Zava, D.; Allais, G.
In: Neurological Sciences, Vol. 34, No. SUPPL. 1, 2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects
T2 - A review of randomized studies
AU - Tullo, V.
AU - Bussone, G.
AU - Omboni, S.
AU - Barbanti, P.
AU - Cortelli, P.
AU - Curone, M.
AU - Peccarisi, C.
AU - Benedetto, C.
AU - Pezzola, D.
AU - Zava, D.
AU - Allais, G.
PY - 2013
Y1 - 2013
N2 - Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p
AB - Migraine might be associated with high blood pressure (BP), which can cause more severe and more difficult to treat forms of headache. To evaluate the efficacy of frovatriptan and other triptans in the acute treatment of migraine, in patients classified according to a history of arterial hypertension, enrolled in three randomized, double-blind, crossover, Italian studies. Migraineurs with or without aura were randomized to frovatriptan 2.5 mg or rizatriptan 10 mg (study 1), frovatriptan 2.5 mg or zolmitriptan 2.5 mg (study 2), frovatriptan 2.5 mg or almotriptan 12.5 mg (study 3). After treating up to three episodes of migraine in 3 months with the first treatment, patients switched to the alternate treatment for the next 3 months. The present analysis assessed triptan efficacy in 60 subjects with a history of treated or untreated essential arterial hypertension (HT) and in 286 normotensive (NT) subjects. During the study, migraine attacks with aura were significantly more prevalent in HT subjects (21 vs. 13 % NT, p
KW - Almotriptan
KW - Arterial hypertension
KW - Frovatriptan
KW - Migraine
KW - Rizatriptan
KW - Zolmitriptan
UR - http://www.scopus.com/inward/record.url?scp=84892544859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892544859&partnerID=8YFLogxK
U2 - 10.1007/s10072-013-1367-z
DO - 10.1007/s10072-013-1367-z
M3 - Article
VL - 34
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 1
ER -